Clearance of pathological antibodies using biomimetic nanoparticles. - Wikidata - awgldk - TriplyDB

Clearance of pathological antibodies using biomimetic nanoparticles.

Clearance of pathological antibodies using biomimetic nanoparticles.

http://www.wikidata.org/entity/Q34218004

about

Biomimetic and synthetic interfaces to tune immune responses Cell or cell membrane-based drug delivery systems Nanoparticles camouflaged in platelet membrane coating as an antibody decoy for the treatment of immune thrombocytopenia.Hydrogel Retaining Toxin-Absorbing Nanosponges for Local Treatment of Methicillin-Resistant Staphylococcus aureus Infection Engineered nanoparticles mimicking cell membranes for toxin neutralization.Synthesis of Nanogels via Cell Membrane-Templated Polymerization.Cell membrane-camouflaged nanoparticles for drug delivery.Detoxification of Organophosphate Poisoning Using Nanoparticle Bioscavengers Coating nanofiber scaffolds with beta cell membrane to promote cell proliferation and function.Safe and Immunocompatible Nanocarriers Cloaked in RBC Membranes for Drug Delivery to Treat Solid Tumors.Nanoparticle-Based Antivirulence Vaccine for the Management of Methicillin-Resistant Staphylococcus aureus Skin Infection.Anticancer Platelet-Mimicking Nanovehicles.Internalized compartments encapsulated nanogels for targeted drug delivery.Biomimetic proteolipid vesicles for targeting inflamed tissues Nano-antidotes for drug overdose and poisoning.Lipid-coated polymeric nanoparticles for cancer drug delivery.Coating nanoparticles with cell membranes for targeted drug delivery.Tolerogenic Nanoparticles to Treat Islet Autoimmunity.Biointerfacing and Applications of Cell Membrane-Coated Nanoparticles.Investigation and optimization of formulation parameters on preparation of targeted anti-CD205 tailored PLGA nanoparticles.Cell membrane-derived nanomaterials for biomedical applications.Biomimetic and bioinspired nanoparticles for targeted drug delivery.In Situ Capture of Bacterial Toxins for Antivirulence Vaccination.Preparation and Application of Cell Membrane-Camouflaged Nanoparticles for Cancer Therapy.Materials design at the interface of nanoparticles and innate immunity.Erythrocyte-Platelet Hybrid Membrane Coating for Enhanced Nanoparticle Functionalization.Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management.Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy.Toxoid Vaccination against Bacterial Infection Using Cell Membrane-Coated Nanoparticles.Engineered biomimetic nanovesicles show intrinsic anti-inflammatory properties for the treatment of inflammatory bowel diseases.Cell Membrane Coating Nanotechnology.Neutralization of cholera toxin with nanoparticle decoys for treatment of cholera.Biomimetic Targeting of Nanoparticles to Immune Cell Subsets via Cognate Antigen Interactions.Engineering nanoparticles to overcome barriers to immunotherapy.Platelet-camouflaged nanococktail: Simultaneous inhibition of drug-resistant tumor growth and metastasis via a cancer cells and tumor vasculature dual-targeting strategy.Staphylococcus aureus modulation of innate immune responses through Toll-like (TLR), (NOD)-like (NLR) and C-type lectin (CLR) receptors Preparation of particulate polymeric therapeutics for medical applications Lipid insertion enables targeted functionalization of paclitaxel-loaded erythrocyte membrane nanosystem by tumor-penetrating bispecific recombinant protein Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment

P2860

Q26801229-522783ED-271A-4838-A4D1-A56CB8E50209 Q28080710-787E58DB-B70F-4F77-A4EF-ADCF6A01A074 Q33435943-52A2A718-5270-4367-ABBD-EC83A573247A Q35706529-8B8D69E6-463D-4D73-86F8-9CCAD7D31AC5 Q35991625-34884602-95F3-4FF2-A627-4F5B14383D14 Q36037531-4744B692-F0D5-47E6-BE2F-DB7AC9C0E741 Q36396004-0BEC5FAD-2A28-4176-98C8-1BFB33359B11 Q36801498-5B9955E4-D99E-4506-8949-1E4363783FF9 Q36900851-F792F3F4-4173-44F0-9E5F-40D4640F4B89 Q36926013-BBD6D230-EC15-4438-8444-99450F852869 Q37016217-A4FD4AF4-3CD0-476E-B34D-77B615C14E46 Q37206537-D2A5D49E-2CB7-47A9-ACA3-444C9940B391 Q37210607-30DCAC2A-6D00-4FA7-90D7-6947469C380F Q37451394-B2CC901E-B66C-4FF2-8422-A30FB4996F8A Q38515174-6F1D6DF6-58D3-411E-A961-508847F7697D Q38556750-51F48084-6FCB-4E41-8798-AEC13DD602CB Q38603358-A1FF7172-BA8E-4E72-8A16-3649D7963FA2 Q38645059-A85DF8D6-1F3B-4C81-9558-4713291FA3FF Q38734878-C7D74587-A0CE-440B-9E4D-BDE7E79BA833 Q38811044-7B766DF9-5E64-400A-BAC5-841C708831EA Q39178313-38F43AC7-AA31-4D03-AF7E-A9750F2136E3 Q39210548-201E12D7-915D-440C-9C3E-4026BFAB260A Q40155457-0C94E3C2-843C-4223-8167-70AD22D15EF9 Q41430285-DB3D6A17-CB52-4928-A27A-04689D9AB4DB Q41915826-826ED5FE-45C5-4726-91BC-4D26FA1D6F56 Q45983074-3502B658-867D-4A1D-A7F8-42091474F05F Q46184518-BFF95825-373D-42EF-89B1-60051B45188A Q47707153-EFEDC5A4-7BAF-45CC-827D-77E1A74F29C0 Q48116102-EE7C40CD-BE77-42C0-B7A7-44F78C115A5B Q49971986-2CF1243B-C69F-4A44-A99B-83BF99A58384 Q52628718-E4E53DA0-24C3-4ABE-9A55-F8D18501DD29 Q52690158-2ABA98DA-F577-4069-A3D8-DA6BD4863557 Q54256935-80BDE124-828D-4A5A-A888-473F48368BC5 Q54991276-C2680BA6-EECA-4A49-8C53-91FD839953E4 Q55379943-CF60CA5D-3603-484B-AE88-7A484AB135E3 Q57163788-948C5F2E-8240-4CA9-8C0C-87435C306F2B Q57498734-CD1782A3-8D03-470F-B021-DEF1113F51CA Q58750896-DB526060-D53D-45E4-A996-EB5002E863B1 Q58781545-A91F8435-A52F-452F-98AA-4227CFF9A524

P2860

Clearance of pathological antibodies using biomimetic nanoparticles.

http://www.wikidata.org/entity/Q34218004

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Clearance of pathological antibodies using biomimetic nanoparticles.

@ast

Clearance of pathological antibodies using biomimetic nanoparticles.

@en

Clearance of pathological antibodies using biomimetic nanoparticles.

@nl

type

label

Clearance of pathological antibodies using biomimetic nanoparticles.

@ast

Clearance of pathological antibodies using biomimetic nanoparticles.

@en

Clearance of pathological antibodies using biomimetic nanoparticles.

@nl

prefLabel

Clearance of pathological antibodies using biomimetic nanoparticles.

@ast

Clearance of pathological antibodies using biomimetic nanoparticles.

@en

Clearance of pathological antibodies using biomimetic nanoparticles.

@nl

P1433

Q34218004-ED9298D5-22FD-4FAE-A448-A05620F2DDBB

P1476

Q34218004-0E01D7F5-DF78-45EF-8752-8681643E8FE0

P2093

Q34218004-1CC000D1-CF55-4D04-A59F-FB7EE88AE715

Q34218004-4B7CEAEC-D13F-4F93-840F-69BDA76D27C9

Q34218004-5BC06EDF-10B7-4DFE-B56A-929304C44079

Q34218004-91E10EDF-C77E-444B-92B9-04C6C3B7EFDF

Q34218004-CF29E398-EE1C-4752-8D24-DD62204192A3

Q34218004-D674B23E-8E50-45FD-8BE6-F61D024AC002

Q34218004-E96F3E4F-4B2B-4AE0-984F-61A2C8E8374A

P2860

Q34218004-00FF7720-114A-4D67-9772-B2C36FB3048F

Q34218004-0E4FFF91-45E2-4528-A270-13E512FAFE7F

Q34218004-12642F20-BC08-4B6A-84A0-2F6CDE270986

Q34218004-1705744F-B86C-425D-AE52-3FCDB72B3D07

Q34218004-181C3353-57D2-4478-B19B-C1EE97573D73

Q34218004-1A998657-467B-47B1-BFB0-6E2C90EFD0F0

Q34218004-1D687A68-051A-4D39-AB6A-55F86F3DC2EB

Q34218004-26E2EFFF-8BF1-4BAA-BFF8-ADE62741A8AA

Q34218004-349AC2CE-437A-49E1-A0CC-96197B04581F

Q34218004-405F0208-182A-4564-B45C-7C444EA8D6F6

P304

Q34218004-7B285E7F-A52C-4741-A5EA-C2DC9822D31B

P31

Q34218004-19F48E54-7FCF-451C-985A-E684AD876F17

P356

Q34218004-9C5948FF-AB8C-4548-B282-680F3E3B6967

P407

Q34218004-D78367FC-6FAF-498D-AC1C-12E709501A87

P433

Q34218004-0457C9A8-A40D-47B5-A5E7-5C5842F7DA7F

P478

Q34218004-36ABD667-B016-45AA-B4C2-F6A773C9CE75

P577

Q34218004-9C18B931-B502-42C9-8FB5-33BA1B070DD6

P5875

Q34218004-F74F3C58-AA7C-4849-9999-6AD30D3DBE25

P698

Q34218004-CD589D3B-1AC1-466C-9CD5-331467A16528

P921

Q34218004-06E9AB3C-5C15-469B-9551-2D13917C740A

Q34218004-5213248B-718A-4D92-BA54-F66920C60441

Q34218004-AC046EC8-F012-46BD-A04E-7C047C6264BC

P932

Q34218004-1831AFB8-B3A9-454B-8924-A510E34BA1A7

P356

PNAS.1412420111

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Clearance of pathological antibodies using biomimetic nanoparticles.

@en

P2093

Brian T Luk

http://www.w3.org/2001/XMLSchema#string

Che-Ming J Hu

http://www.w3.org/2001/XMLSchema#string

Jonathan A Copp

http://www.w3.org/2001/XMLSchema#string

Kang Zhang

http://www.w3.org/2001/XMLSchema#string

Liangfang Zhang

http://www.w3.org/2001/XMLSchema#string

Ronnie H Fang

http://www.w3.org/2001/XMLSchema#string

Weiwei Gao

http://www.w3.org/2001/XMLSchema#string

P2860

Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform

Anti-inflammatory therapy in chronic disease: challenges and opportunities

FcgammaRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia

Management and preparedness for infusion and hypersensitivity reactions.

Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity.

A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia.

Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders.

Epidemiology and estimated population burden of selected autoimmune diseases in the United States.

Evidence-based management of bullous pemphigoid.

P304

13481-13486

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1412420111

http://www.w3.org/2001/XMLSchema#string

P407

P433

37

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265419791

http://www.w3.org/2001/XMLSchema#string

P698

25197051

http://www.w3.org/2001/XMLSchema#string

P921

P932

4169917

http://www.w3.org/2001/XMLSchema#string